Novel L-nucleoside analogue, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia

• Aniket Bankar,
• Thirushi Piyumika Siriwardena,
• Biljana Rizoska,
• Christina Rydergård,
• Helen Kylefjord,
• Vilma Rraklli,
• Anders Eneroth,
• Pedro Pinho,
• Stefan Norin,
• Johan Bylund,
• Sara Moses,
• Richard Bethell,
• Simon Kavanagh,
• Neil Maclean,
• Marcela Gronda,
• Xiaoming Wang,
• Rose Hurren,
• Mark D. Minden,
• Paul Targett-Adams,
• Aaron D. Schimmer,
• Mark Albertella

Affiliations

Aniket Bankar

Princess Margaret Cancer Center, University Health Network, Ontario, Canada;

Thirushi Piyumika Siriwardena

Princess Margaret Cancer Center, University Health Network, Ontario, Canada;

Biljana Rizoska

Medivir AB,Huddinge, Sweden;

Christina Rydergård

Medivir AB, Huddinge, Sweden

Helen Kylefjord

Medivir AB, Huddinge, Sweden

Vilma Rraklli

Medivir AB, Huddinge, Sweden

Anders Eneroth

Medivir AB, Huddinge, Sweden

Pedro Pinho

Medivir AB, Huddinge, Sweden

Stefan Norin

Medivir AB, Huddinge, Sweden

Johan Bylund

Medivir AB, Huddinge, Sweden

Sara Moses

Medivir AB, Huddinge, Sweden

Richard Bethell

Medivir AB, Huddinge, Sweden

Simon Kavanagh

Princess Margaret Cancer Center, University Health Network, Ontario, Canada;

Neil Maclean

Princess Margaret Cancer Center, University Health Network, Ontario, Canada;

Marcela Gronda

Princess Margaret Cancer Center, University Health Network, Ontario, Canada;

Xiaoming Wang

Princess Margaret Cancer Center, University Health Network, Ontario, Canada;

Rose Hurren

Princess Margaret Cancer Center, University Health Network, Ontario, Canada;

Mark D. Minden

Princess Margaret Cancer Center, University Health Network, Ontario, Canada;

Paul Targett-Adams

Medivir AB, Huddinge, Sweden

Aaron D. Schimmer

Princess Margaret Cancer Center, University Health Network, Ontario, Canada;

Mark Albertella

Medivir AB, Huddinge, Sweden